The CSL Limited (ASX: CSL) share price has started the week in the red.
In afternoon trade, the biotherapeutics giant’s shares are down 1.5% to $276.79.
Where next for the CSL share price?
According to a note out of Citi, its analysts believe the CSL share price could be heading higher from here.
The note reveals that its analysts have retained their buy rating and $335.00 price target on the company’s shares.
Based on the current CSL share price, this implies potential upside of 21% for investors over the next 12 months.
What is the broker saying?
Citi has been looking at industry data and believes that it is pointing to continued improvement in plasma collections and strong underlying demand.
It believes this supports its view that the key drivers of the CSL share price will shift in the near future to product demand and the acquisition of Vifor Pharma.
It commented:
The latest quarterly results from Grifols, Takeda and Haemonetics, and recent comments from CSL are all highlighting the continued improvement in plasma collection and strong underlying demand for plasma products.
This is consistent with our view that over the next six months, we expect the market to shift its focus to the strong underlying plasma product demand, and the closure the Vifor deal, both of which should lead to strength in the share price.
Our FY23-24 EPS estimates remain 5-6% above consensus (we have included the Vifor consensus estimates in our forecasts). The next catalyst will be the closure of the Vifor transaction which is now expected to complete by the end of Sept (previously June).
All in all, the broker appears to see the CSL share price as trading at an attractive level for investors at present and I would have to agree due to the points outlined above.
The post Where next for the CSL share price? appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- CSL share price cracks under Vifor Pharma acquisition delay
- Why CSL, Dicker Data, Lifestyle Communities, and Money3 shares are rising today
- What is driving the CSL share price higher today?
- 2 ASX shares at ‘appealing’ buy prices right now
- How did the CSL share price escape the carnage today?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/HbXv3nA
Leave a Reply